CytomX Therapeutics CTMX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $10.26M-79.9% | $663K-98.3% | $5.96M-82.2% | $18.66M-25.7% | $50.92M+22.8% | ||
| $19.24M+2.0% | $21.24M+43.6% | $15.3M-28.4% | $13.32M-47.1% | $18.87M-14.4% | ||
| $10.69M+13.4% | $7.36M+30.9% | $6.43M-19.2% | $6.62M-21.1% | $9.43M+21.6% | ||
| $29.93M+5.8% | $28.6M+40.1% | $21.73M-25.9% | $19.94M-40.6% | $28.3M-5.1% | ||
| $29.93M+5.8% | $28.6M+40.1% | $21.73M-25.9% | $19.94M-40.6% | $28.3M-5.1% | ||
| -$19.67M-187% | -$27.93M-258% | -$15.77M-484% | -$1.29M+84.8% | $22.62M+94.1% | ||
| -191.8%-236pp | -4,213%-4,259pp | -264.4%-277pp | -6.9%+26.8pp | 44.4%+16.3pp | ||
| $1.49M+56.0% | $1.48M+15.9% | $1.59M-6.0% | $1.18M-40.2% | $955K-56.5% | ||
| -$7K-164% | —— | $5K+171% | $17K+950% | $11K+200% | ||
| -$18.19M-177% | -$26.46M-240% | -$14.17M-344% | -$91K+98.6% | $23.59M+70.4% | ||
| $59K-4.8% | $54K-12.9% | $58K-4.9% | $63K+23.5% | $62K+26.5% | ||
| -$18.25M-178% | -$26.51M-240% | -$14.23M-348% | -$154K+97.6% | $23.53M+70.6% | ||
| -177.9%-224pp | -3,998.5%-4,048pp | -238.6%-256pp | -0.8%+25.2pp | 46.2%+12.9pp | ||
| -$0.10-137% | -$0.22-196% | -$0.09-229% | -$0.00+100% | $0.27+58.8% | ||
| -$0.10-137% | -$0.22-196% | -$0.09-229% | -$0.00+100% | $0.27+58.8% | ||
| -$0.10-137% | -$0.22-196% | -$0.09-229% | -$0.00+100% | $0.27+58.8% | ||
| 177.3M+103% | 137.9M+62.8% | 165M+93.7% | 129.1M+52.1% | 87.2M+5.5% | ||
| 177.3M+103% | 137.9M+63.4% | 165M+93.9% | 129.1M+52.1% | 87.1M+6.2% | ||
| -$0.1-137% | -$0.22-196% | -$0.09-229% | -$0+100% | $0.27+58.8% | ||
| -$0.1-137% | -$0.22-196% | -$0.09-229% | -$0+100% | $0.27+58.8% | ||
| -$18.26M-178% | -$26.5M-241% | -$14.16M-345% | -$120K+98.2% | $23.5M+71.7% | ||
| —— | -$750.5K— | -$750.5K— | -$750.5K— | -$750.5K— | ||
| -$9K+67.9% | $7K+154% | $71K+61.4% | $34K+467% | -$28K+73.3% | ||
| -$7K-164% | —— | $5K+171% | $17K+950% | $11K+200% | ||
| $10.26M-79.9% | $663K-98.3% | $5.96M-82.2% | $18.66M-25.7% | $50.92M+22.8% | ||
| -$19.67M-187% | -$27.93M-258% | -$15.77M-484% | -$1.29M+84.8% | $22.62M+94.1% | ||
| -$19.64M-187% | -$27.9M-257% | -$15.73M-479% | -$1.25M+85.2% | $22.66M+93.8% | ||
| -$19.64M-187% | -$27.9M-257% | -$15.73M-479% | -$1.25M+85.2% | $22.66M+93.8% | ||
| -191.4%-236pp | -4,207.4%-4,254pp | -263.8%-276pp | -6.7%+26.8pp | 44.5%+16.3pp | ||
| -$19.67M-187% | -$27.93M-258% | -$15.77M-484% | -$1.29M+84.8% | $22.62M+94.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is CytomX Therapeutics's revenue?
- CytomX Therapeutics (CTMX) generated $35.5M in revenue over the trailing twelve months, down 75.9% year over year.
- Is CytomX Therapeutics profitable?
- CytomX Therapeutics is not currently profitable: it reported a net loss of $59.1M over the trailing twelve months, a -166.4% net margin.
- What is CytomX Therapeutics's earnings per share?
- CytomX Therapeutics's diluted EPS over the trailing twelve months is $-0.41.
- Where does CytomX Therapeutics's income statement data come from?
- Every line is extracted from CytomX Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
